Compare HCA Health Inc (HCA) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Heron Therapeutics Inc — how do they compare? HCA Health Inc trades at $443.69 (market cap $96.35B), while Heron Therapeutics Inc trades at $0.37 (market cap $68.01M). The key difference: HCA Health Inc is far larger — about 1416.7× Heron Therapeutics Inc's market cap, and HCA Health Inc pays a 0.7% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Heron Therapeutics Inc for 35 Days on average.
| HCA | HRTX | |
|---|---|---|
Market Cap | $96.35B | $68.01M |
Volume | 1,079,453 | 1,891,941 |
Sector | Health | Health |
52-Week High | $545.13 | $1.49 |
52-Week Low | $361.32 | $0.27 |
Typical Hold Time | 76 Days | 35 Days |
Enterprise Value | $146.88B | $174.75M |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
